news
Specific mechanism found to control transition from acute to chronic pain
A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
List view / Grid view
Drug Development
news
Gene therapy shows promise for Angelman syndrome treatment
A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
article
Peptides: a promising alternative to opioids for chronic pain relief
In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
news
$2.6 million granted to create pan-coronavirus vaccine
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
news
Novel strategy successfully suppresses HIV infection in mice
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
news
$7.5 million to fund senescent cell research for age-related disease
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
news
Novel method refines cryogenic electron microscopy (cyro-EM)
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
news
Highly potent antiviral against dengue could prevent spread of virus
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news
Discovery unveils genetic risk factor shared by Alzheimer’s and COVID-19
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
article
Are computer simulations the future of rapid COVID-19 drug development?
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
news
Pre-clinical trials to test if psychedelic drugs reduce alcohol consumption
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
news
Psilera to collaborate with NIDA on pre-clinical psychedelic studies
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
article
AI & Informatics: Drug discovery and development – industry survey infographic
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
